Veracyte Analyst Ratings
Veracyte Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/10/2023 | 53.64% | Stephens & Co. | → $34 | Reiterates | Overweight → Overweight |
| 08/09/2023 | 3.93% | Morgan Stanley | $22 → $23 | Maintains | Underweight |
| 08/09/2023 | 58.16% | Needham | $34 → $35 | Maintains | Buy |
| 05/08/2023 | 35.56% | Stephens & Co. | → $30 | Reiterates | → Overweight |
| 02/23/2023 | 53.64% | Needham | $33 → $34 | Maintains | Buy |
| 01/18/2023 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 01/05/2023 | 49.12% | Scotiabank | → $33 | Initiates Coverage On | → Sector Outperform |
| 11/04/2022 | -0.59% | Morgan Stanley | $23 → $22 | Maintains | Underweight |
| 11/04/2022 | 22.01% | Raymond James | $31 → $27 | Maintains | Outperform |
| 11/03/2022 | 49.12% | Needham | $31 → $33 | Maintains | Buy |
| 11/03/2022 | 58.16% | SVB Leerink | $30 → $35 | Maintains | Outperform |
| 08/04/2022 | 40.08% | Raymond James | $30 → $31 | Maintains | Outperform |
| 08/03/2022 | 40.08% | Needham | $26 → $31 | Maintains | Buy |
| 05/05/2022 | 35.56% | Stephens & Co. | $44 → $30 | Maintains | Overweight |
| 05/04/2022 | 3.93% | Morgan Stanley | $25 → $23 | Maintains | Underweight |
| 05/04/2022 | 35.56% | Raymond James | $34 → $30 | Maintains | Outperform |
| 05/04/2022 | 17.49% | Needham | $31 → $26 | Maintains | Buy |
| 03/15/2022 | 40.08% | Needham | $35 → $31 | Maintains | Buy |
| 03/02/2022 | 98.83% | Stephens & Co. | $52 → $44 | Maintains | Overweight |
| 03/01/2022 | 53.64% | Raymond James | $62 → $34 | Maintains | Outperform |
| 03/01/2022 | 80.75% | SVB Leerink | $45 → $40 | Maintains | Outperform |
| 01/07/2022 | 134.98% | Stephens & Co. | → $52 | Initiates Coverage On | → Overweight |
| 11/10/2021 | 180.16% | Raymond James | $50 → $62 | Maintains | Outperform |
| 07/30/2021 | 89.79% | Morgan Stanley | $45 → $42 | Maintains | Underweight |
| 07/30/2021 | 148.53% | Needham | $54 → $55 | Maintains | Buy |
| 07/30/2021 | 171.13% | SVB Leerink | $55 → $60 | Maintains | Outperform |
| 07/14/2021 | 148.53% | SVB Leerink | $65 → $55 | Maintains | Outperform |
| 06/28/2021 | 125.94% | Raymond James | $45 → $50 | Maintains | Outperform |
| 06/15/2021 | 103.34% | Raymond James | → $45 | Initiates Coverage On | → Outperform |
| 05/18/2021 | 148.53% | Truist Securities | $84 → $55 | Maintains | Buy |
| 05/12/2021 | 103.34% | Morgan Stanley | $65 → $45 | Maintains | Underweight |
| 05/11/2021 | 193.72% | SVB Leerink | $75 → $65 | Maintains | Outperform |
| 05/11/2021 | 144.01% | Needham | $88 → $54 | Maintains | Buy |
| 02/22/2021 | 193.72% | Morgan Stanley | $35 → $65 | Maintains | Underweight |
| 02/19/2021 | 193.72% | Morgan Stanley | $35 → $65 | Maintains | Underweight |
| 02/18/2021 | 284.09% | SVB Leerink | $83 → $85 | Maintains | Outperform |
| 02/08/2021 | 275.06% | SVB Leerink | $40 → $83 | Maintains | Outperform |
| 01/28/2021 | 175.64% | Truist Securities | → $61 | Initiates Coverage On | → Buy |
| 11/10/2020 | — | Keybanc | Initiates Coverage On | → Sector Weight | |
| 11/04/2020 | 89.79% | BTIG | $38 → $42 | Maintains | Buy |
| 11/03/2020 | 80.75% | Needham | $37 → $40 | Maintains | Buy |
| 11/03/2020 | 80.75% | SVB Leerink | $37 → $40 | Maintains | Outperform |
| 09/09/2020 | 58.16% | Morgan Stanley | → $35 | Initiates Coverage On | → Underweight |
| 07/31/2020 | 67.19% | SVB Leerink | $32 → $37 | Maintains | Outperform |
| 07/31/2020 | 67.19% | Needham | $30 → $37 | Maintains | Buy |
| 05/07/2020 | 44.6% | SVB Leerink | $29 → $32 | Maintains | Outperform |
| 02/26/2020 | 35.56% | Needham | $34 → $30 | Maintains | Buy |
| 07/31/2019 | — | Lake Street | Initiates Coverage On | → Buy | |
| 07/02/2019 | 49.12% | Needham | → $33 | Initiates Coverage On | → Buy |
| 11/29/2018 | — | Janney Montgomery Scott | Downgrades | Buy → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月10日 | 53.64% | 斯蒂芬斯公司 | →$34 | 重申 | 超重→超重 |
| 08/09/2023 | 3.93% | 摩根士丹利 | $22→$23 | 維護 | 體重不足 |
| 08/09/2023 | 58.16% | 李約瑟 | $34→$35 | 維護 | 買 |
| 05/08/2023 | 35.56% | 斯蒂芬斯公司 | →$30 | 重申 | →超重 |
| 02/23/2023 | 53.64% | 李約瑟 | $33→$34 | 維護 | 買 |
| 01/18/2023 | - | 雷蒙德·詹姆斯 | 評級下調 | 跑贏→市場表現 | |
| 01/05/2023 | 49.12% | 加拿大豐業銀行 | →$33 | 開始承保 | →板塊跑贏大盤 |
| 11/04/2022 | -0.59% | 摩根士丹利 | $23→$22 | 維護 | 體重不足 |
| 11/04/2022 | 22.01% | 雷蒙德·詹姆斯 | $31→$27 | 維護 | 跑贏大盤 |
| 11/03/2022 | 49.12% | 李約瑟 | $31→$33 | 維護 | 買 |
| 11/03/2022 | 58.16% | SVB Leerink | $30→$35 | 維護 | 跑贏大盤 |
| 08/04/2022 | 40.08% | 雷蒙德·詹姆斯 | $30→$31 | 維護 | 跑贏大盤 |
| 08/03/2022 | 40.08% | 李約瑟 | $26→$31 | 維護 | 買 |
| 05/05/2022 | 35.56% | 斯蒂芬斯公司 | $44→$30 | 維護 | 超重 |
| 05/04/2022 | 3.93% | 摩根士丹利 | $25→$23 | 維護 | 體重不足 |
| 05/04/2022 | 35.56% | 雷蒙德·詹姆斯 | $34→$30 | 維護 | 跑贏大盤 |
| 05/04/2022 | 17.49% | 李約瑟 | $31→$26 | 維護 | 買 |
| 03/15/2022 | 40.08% | 李約瑟 | $35→$31 | 維護 | 買 |
| 03/02/2022 | 98.83% | 斯蒂芬斯公司 | $52→$44 | 維護 | 超重 |
| 03/01/2022 | 53.64% | 雷蒙德·詹姆斯 | $62→$34 | 維護 | 跑贏大盤 |
| 03/01/2022 | 80.75% | SVB Leerink | $45→$40 | 維護 | 跑贏大盤 |
| 01/07/2022 | 134.98% | 斯蒂芬斯公司 | →$52 | 開始承保 | →超重 |
| 2021年11月10日 | 180.16% | 雷蒙德·詹姆斯 | $50→$62 | 維護 | 跑贏大盤 |
| 07/30/2021 | 89.79% | 摩根士丹利 | $45→$42 | 維護 | 體重不足 |
| 07/30/2021 | 148.53% | 李約瑟 | $54→$55 | 維護 | 買 |
| 07/30/2021 | 171.13% | SVB Leerink | $55→$60 | 維護 | 跑贏大盤 |
| 07/14/2021 | 148.53% | SVB Leerink | $65→$55 | 維護 | 跑贏大盤 |
| 2021/06/28 | 125.94% | 雷蒙德·詹姆斯 | $45→$50 | 維護 | 跑贏大盤 |
| 2021/06/15 | 103.34% | 雷蒙德·詹姆斯 | →$45 | 開始承保 | →跑贏大盤 |
| 2021/05/18 | 148.53% | Truist證券 | $84→$55 | 維護 | 買 |
| 2021/05/12 | 103.34% | 摩根士丹利 | $65→$45 | 維護 | 體重不足 |
| 2021/11/05 | 193.72% | SVB Leerink | $75→$65 | 維護 | 跑贏大盤 |
| 2021/11/05 | 144.01% | 李約瑟 | $88→$54 | 維護 | 買 |
| 02/22/2021 | 193.72% | 摩根士丹利 | $35→$65 | 維護 | 體重不足 |
| 02/19/2021 | 193.72% | 摩根士丹利 | $35→$65 | 維護 | 體重不足 |
| 02/18/2021 | 284.09% | SVB Leerink | $83→$85 | 維護 | 跑贏大盤 |
| 02/08/2021 | 275.06% | SVB Leerink | $40→$83 | 維護 | 跑贏大盤 |
| 2021年1月28日 | 175.64% | Truist證券 | →$61 | 開始承保 | →購買 |
| 11/10/2020 | - | KeyBanc | 開始承保 | →行業權重 | |
| 11/04/2020 | 89.79% | BTIG | $38→$42 | 維護 | 買 |
| 11/03/2020 | 80.75% | 李約瑟 | $37→$40 | 維護 | 買 |
| 11/03/2020 | 80.75% | SVB Leerink | $37→$40 | 維護 | 跑贏大盤 |
| 09/09/2020 | 58.16% | 摩根士丹利 | →$35 | 開始承保 | →減持 |
| 07/31/2020 | 67.19% | SVB Leerink | $32→$37 | 維護 | 跑贏大盤 |
| 07/31/2020 | 67.19% | 李約瑟 | $30→$37 | 維護 | 買 |
| 05/07/2020 | 44.6% | SVB Leerink | $29→$32 | 維護 | 跑贏大盤 |
| 02/26/2020 | 35.56% | 李約瑟 | $34→$30 | 維護 | 買 |
| 2019年07月31日 | - | 萊克街 | 開始承保 | →購買 | |
| 2019年07月02日 | 49.12% | 李約瑟 | →$33 | 開始承保 | →購買 |
| 2018年11月29日 | - | 詹尼·蒙哥馬利·斯科特 | 評級下調 | 購買→中性 |
What is the target price for Veracyte (VCYT)?
Veracyte的目標價是多少？
The latest price target for Veracyte (NASDAQ: VCYT) was reported by Stephens & Co. on October 10, 2023. The analyst firm set a price target for $34.00 expecting VCYT to rise to within 12 months (a possible 53.64% upside). 11 analyst firms have reported ratings in the last year.
斯蒂芬斯公司於2023年10月10日報道了Veracyte(納斯達克代碼：VCyT)的最新目標價。這家分析公司將目標價定為34.00美元，預計VCyT將在12個月內上漲至53.64%。過去一年，有11家分析公司公佈了評級。
What is the most recent analyst rating for Veracyte (VCYT)?
Veracyte的最新分析師評級是什麼？
The latest analyst rating for Veracyte (NASDAQ: VCYT) was provided by Stephens & Co., and Veracyte reiterated their overweight rating.
斯蒂芬斯公司提供了對Veracyte(納斯達克代碼：VCYT)的最新分析師評級，Veracyte重申了其增持評級。
When is the next analyst rating going to be posted or updated for Veracyte (VCYT)?
Veracyte的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Veracyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Veracyte was filed on October 10, 2023 so you should expect the next rating to be made available sometime around October 10, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Veracyte的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Veracyte的上一次評級是在2023年10月10日提交的，所以你應該預計下一次評級將在2024年10月10日左右的某個時候公佈。
Is the Analyst Rating Veracyte (VCYT) correct?
分析師評級Veracyte(VCyT)正確嗎？
While ratings are subjective and will change, the latest Veracyte (VCYT) rating was a reiterated with a price target of $0.00 to $34.00. The current price Veracyte (VCYT) is trading at is $22.13, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Veracyte(VCyT)評級被重申，目標價在0.00美元至34.00美元之間。Veracyte目前的交易價格為22.13美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。